Last checked at 11 Jan 2023 09:30
CORRECT: Getech signs deal; AfriTin confirms name change
(Corrects that Zenith Energy is based in Canada, not in Scotland.)
Read more
Sponsored Content
Don't want ads? Click here
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here
Don't want ads? Click here
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Sponsored Content
IQ-AI Share News (IQAI)
IQAI Share
Price
IQAI Share
News
IQAI Share
Chat2
IQAI Share
Trades
IQAI
Live RNS
IQAI Share
Charts
IQAI Level 2
Console
IQAI Live
Share Price
IQAI Broker
Ratings
IQAI Directors
Deals
IQAI Financial
Diary
IQAI
Fundamentals
IQAI Short
Positions
IQAI
Media
IQAI Company
Research
IQAI Company
Timeline
IQ-AI Information
Share Price Information for IQ-AI (IQAI)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
0.835
Bid:
0.80
Ask:
0.87
Change:
0.00 (0.00%)
Spread:
0.07 (8.75%)
Open:
0.835
High:
0.835
Low:
0.835
Prev. Close:
0.835
Last checked at -
Sponsored Content
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Timelines are a member only feature
Login to your account
Don't have an account? Click here to register.10 Jan 2023 21:34
TRADING UPDATES: Getech signs deal; AfriTin confirms name change
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more16 Aug 2022 14:39
IN BRIEF: IQ-AI shares plummet on widening interim loss
IQ-AI Ltd - Jersey-based medical services firm - Posts larger interim pretax loss due to increased administrative costs. Pretax loss in the half-year to June 30 widens to GBP330,584 from GBP207,135 a year ago. Revenue climbs 7.2% to GBP255,609 from GBP238,488. However, revenue growth is offset by administrative costs increasing by 34% to GBP583,346 from GBP436,247.
Read more11 Jul 2022 13:34
IN BRIEF: IQ-AI launches IB Clinic on Bayer Calantic platform
IQ-AI Ltd - Jersey-based medical services firm - Says its medical imaging analysis software, IB Clinic, is now available via the newly launched Bayer Calantic platform. The distribution partnership continues its strategy of making IB Clinic accessible to healthcare providers through widespread networks, the company adds.
Read more31 May 2022 13:26
IN BRIEF: IQ-AI shares rise with submission of application to US FDA
IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC submits 510(k) application to US Food & Drug Administration for IB Zero G, an artificial intelligence software that eliminates the need for gadolinium-based contrast agents in routine magnetic imagining exams. "The FDA 510(k) submission is the first step in potentially transforming the global gadolinium-based contrast agent market and introducing a paradigm shift in radiology departments," company says.
Read more31 May 2022 10:44
SMALL-CAP WINNERS & LOSERS: IQ-AI's IB Zero G moves closer to approval
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.
Read more3 May 2022 16:36
IQ-AI imaging technology gets vote of confidence in US study
(Alliance News) - IQ-AI Ltd unit Imaging Biometrics on Tuesday said a study concluded its imaging technology was successful in identifying tumours.
Read more28 Apr 2022 19:25
TRADING UPDATES: Impellam's first quarter beats pre-virus levels
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more9 Mar 2022 20:30
IN BRIEF: IQ-AI opens oral gallium malotate trial for enrolment
IQ-AI Ltd - Jersey-based medical services firm - Says phase one clinical trial for oral gallium maltolate is open for enrolment. Patient recruitment in the trial is underway and potential volunteers that meet the inclusion criteria have already been identified, it notes. Phase one dose escalation study is designed to determine the optimal dose of GaM that can be administered safely. It is the first-in-human clinical trial for an oral form of GaM to be used in patients with high-grade brain tumours, it adds.
Read more11 Nov 2021 19:43
TRADING UPDATES: Beximco profit rises; Tremor buoyant as sales rise
TRADING UPDATES: Beximco profit rises; Tremor buoyant as sales rise
Read more28 Oct 2021 19:19
TRADING UPDATES: Hunting hurt by Ida; React revenue short of consensus
TRADING UPDATES: Hunting hurt by Ida; React revenue short of consensus
Read more7 Oct 2021 22:08
TRADING UPDATES: Marlowe buys; Galliford snaps up nmcn's Water unit
TRADING UPDATES: Marlowe buys; Galliford snaps up nmcn's Water unit
Read more22 Sep 2021 19:31
TRADING UPDATES: Clinigen signs Copiktra deal; Alien "really pleased"
TRADING UPDATES: Clinigen signs Copiktra deal; Alien "really pleased"
Read more17 Sep 2021 17:53
IN BRIEF: IQ-AI sells several licenses of Imaging Biometrics software
IN BRIEF: IQ-AI sells several licenses of Imaging Biometrics software
Read more10 Sep 2021 16:14
TRADING UPDATES: Argo gets GBP18 million loan; Genedrive fundraises
TRADING UPDATES: Argo gets GBP18 million loan; Genedrive fundraises
Read more
Sponsored Content
